Jubilant Pharmova Limited (JUBLPHARMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jubilant Pharmova Limited (JUBLPHARMA) has a cash flow conversion efficiency ratio of 0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs3.69 Billion ≈ $39.91 Million USD) by net assets (Rs65.72 Billion ≈ $710.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jubilant Pharmova Limited - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Jubilant Pharmova Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read JUBLPHARMA total debt and obligations for a breakdown of total debt and financial obligations.
Jubilant Pharmova Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jubilant Pharmova Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BlueNord ASA
OL:BNOR
|
0.553x |
|
JSL Construction & Development Co Ltd
TW:2540
|
-0.226x |
|
Pexa Group Ltd
AU:PXA
|
0.053x |
|
EUTEL.CO.SP.ADR 1/4/ EO1
F:E3B0
|
N/A |
|
Telecom Argentina
BA:TECO2
|
0.156x |
|
Shenzhen Hello Tech Energy Co. Ltd. A
SHE:301327
|
N/A |
|
CPT Technology Group Co Ltd
SHE:000536
|
0.052x |
|
Caisse Regionale de Credit Agricole Mutuel du Languedoc
PA:CRLA
|
0.029x |
Annual Cash Flow Conversion Efficiency for Jubilant Pharmova Limited (2004–2025)
The table below shows the annual cash flow conversion efficiency of Jubilant Pharmova Limited from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see JUBLPHARMA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs62.39 Billion ≈ $674.68 Million |
Rs10.72 Billion ≈ $115.94 Million |
0.172x | -4.09% |
| 2024-03-31 | Rs54.21 Billion ≈ $586.27 Million |
Rs9.71 Billion ≈ $105.04 Million |
0.179x | +46.22% |
| 2023-03-31 | Rs53.92 Billion ≈ $583.10 Million |
Rs6.61 Billion ≈ $71.45 Million |
0.123x | -22.22% |
| 2022-03-31 | Rs53.16 Billion ≈ $574.95 Million |
Rs8.38 Billion ≈ $90.58 Million |
0.158x | -58.14% |
| 2021-03-31 | Rs47.42 Billion ≈ $512.78 Million |
Rs17.84 Billion ≈ $192.96 Million |
0.376x | +36.67% |
| 2020-03-31 | Rs56.04 Billion ≈ $606.04 Million |
Rs15.43 Billion ≈ $166.86 Million |
0.275x | +18.06% |
| 2019-03-31 | Rs48.09 Billion ≈ $520.08 Million |
Rs11.22 Billion ≈ $121.29 Million |
0.233x | -27.79% |
| 2018-03-31 | Rs40.35 Billion ≈ $436.37 Million |
Rs13.03 Billion ≈ $140.94 Million |
0.323x | -13.51% |
| 2017-03-31 | Rs33.97 Billion ≈ $367.35 Million |
Rs12.68 Billion ≈ $137.18 Million |
0.373x | -0.53% |
| 2016-03-31 | Rs29.10 Billion ≈ $314.66 Million |
Rs10.92 Billion ≈ $118.13 Million |
0.375x | +17.60% |
| 2015-03-31 | Rs24.54 Billion ≈ $265.34 Million |
Rs7.83 Billion ≈ $84.71 Million |
0.319x | +10.75% |
| 2014-03-31 | Rs27.84 Billion ≈ $301.13 Million |
Rs8.03 Billion ≈ $86.80 Million |
0.288x | -22.56% |
| 2013-03-31 | Rs26.06 Billion ≈ $281.82 Million |
Rs9.70 Billion ≈ $104.90 Million |
0.372x | +26.19% |
| 2012-03-31 | Rs23.99 Billion ≈ $259.41 Million |
Rs7.08 Billion ≈ $76.52 Million |
0.295x | +68.29% |
| 2011-03-31 | Rs22.14 Billion ≈ $239.44 Million |
Rs3.88 Billion ≈ $41.97 Million |
0.175x | -44.69% |
| 2010-03-31 | Rs22.39 Billion ≈ $242.17 Million |
Rs7.10 Billion ≈ $76.74 Million |
0.317x | -28.02% |
| 2009-03-31 | Rs12.68 Billion ≈ $137.08 Million |
Rs5.58 Billion ≈ $60.35 Million |
0.440x | +21.03% |
| 2008-03-31 | Rs12.56 Billion ≈ $135.85 Million |
Rs4.57 Billion ≈ $49.42 Million |
0.364x | +72.91% |
| 2007-03-31 | Rs9.06 Billion ≈ $98.00 Million |
Rs1.91 Billion ≈ $20.62 Million |
0.210x | +1147.30% |
| 2006-03-31 | Rs8.41 Billion ≈ $90.93 Million |
Rs141.82 Million ≈ $1.53 Million |
0.017x | -92.38% |
| 2005-03-31 | Rs5.04 Billion ≈ $54.56 Million |
Rs1.12 Billion ≈ $12.08 Million |
0.221x | -44.92% |
| 2004-03-31 | Rs2.10 Billion ≈ $22.69 Million |
Rs843.14 Million ≈ $9.12 Million |
0.402x | -- |
About Jubilant Pharmova Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment o… Read more